ZLAB Zai Lab Ltd

  1. Stocks
  2. Healthcare
  3. NASDAQ: ZLAB

Price (delayed)

$25.23

Market cap

$2.48B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.1

Enterprise value

$1.64B

Zai Lab ) is an innovative commercial stage biopharmaceutical company focused on bringing transformative medicines for cancer, infectious and autoimmune diseases to patients in China and around the world. To ...

Highlights
ZLAB's gross profit is up by 44% year-on-year and by 9% since the previous quarter
Zai Lab's revenue has increased by 38% YoY and by 9% from the previous quarter
The equity has contracted by 23% YoY and by 7% from the previous quarter
The quick ratio is down by 11% since the previous quarter and by 8% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://www.zailaboratory.com
Peers: OGN

Key stats

What are the main financial stats of ZLAB
Market
Shares outstanding
98.39M
Market cap
$2.48B
Enterprise value
$1.64B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.65
Price to sales (P/S)
9.67
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.52
Earnings
Revenue
$251.8M
EBIT
-$393M
EBITDA
-$375.09M
Free cash flow
-$369.82M
Per share
EPS
-$4.1
Free cash flow per share
-$3.83
Book value per share
$9.52
Revenue per share
$2.61
TBVPS
$11.42
Balance sheet
Total assets
$1.11B
Total liabilities
$174.06M
Debt
$19.05M
Equity
$932.31M
Working capital
$884.15M
Liquidity
Debt to equity
0.02
Current ratio
7.63
Quick ratio
7.07
Net debt/EBITDA
2.24
Margins
EBITDA margin
-149%
Gross margin
65.8%
Net margin
-156.1%
Operating margin
-134.6%
Efficiency
Return on assets
-32.8%
Return on equity
-38.5%
Return on invested capital
-369.4%
Return on capital employed
-40.4%
Return on sales
-156.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ZLAB stock price

How has the Zai Lab stock price performed over time
Intraday
1.24%
1 week
-0.63%
1 month
4.95%
1 year
-35.04%
YTD
-17.82%
QTD
-9.02%

Financial performance

How have Zai Lab's revenue and profit performed over time
Revenue
$251.8M
Gross profit
$165.73M
Operating income
-$338.97M
Net income
-$393M
Gross margin
65.8%
Net margin
-156.1%
The company's operating margin has surged by 51% YoY and by 12% QoQ
The net margin has grown by 46% YoY and by 12% from the previous quarter
ZLAB's gross profit is up by 44% year-on-year and by 9% since the previous quarter
Zai Lab's revenue has increased by 38% YoY and by 9% from the previous quarter

Growth

What is Zai Lab's growth rate over time

Valuation

What is Zai Lab stock price valuation
P/E
N/A
P/B
2.65
P/S
9.67
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.52
The EPS has grown by 27% YoY and by 2.4% from the previous quarter
The stock's P/B is 56% below its 5-year quarterly average of 5.9 and 13% below its last 4 quarters average of 3.0
The equity has contracted by 23% YoY and by 7% from the previous quarter
ZLAB's price to sales (P/S) is 99% lower than its 5-year quarterly average of 717.1 and 30% lower than its last 4 quarters average of 13.7
Zai Lab's revenue has increased by 38% YoY and by 9% from the previous quarter

Efficiency

How efficient is Zai Lab business performance
Zai Lab's return on invested capital has shrunk by 98% QoQ
The ROS has grown by 46% YoY and by 12% from the previous quarter
The ROA has grown by 3% YoY but it has contracted by 2.2% from the previous quarter
ZLAB's ROE is down by 2.4% QoQ

Dividends

What is ZLAB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ZLAB.

Financial health

How did Zai Lab financials performed over time
The total assets has contracted by 22% YoY and by 5% from the previous quarter
The company's total liabilities fell by 16% YoY but it rose by 3.1% QoQ
The debt is 98% less than the equity
The equity has contracted by 23% YoY and by 7% from the previous quarter
The debt has contracted by 6% from the previous quarter and by 3.7% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.